Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified. The big Swiss ...

PSMA-targeted radioligand therapies (PRLT) for metastatic castration-resistant prostate cancer (mCRPC ... decline were not affected by cancer type, previous treatment, or combination therapies.

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

"After a while, I forgot that I was doing a remote surgery," Cleveland Clinic urologist Dr. Ruben Olivares said of EDAP's ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer ...

The report estimates that more than 158,000 prostate cancer patients worldwide are eligible for targeted radioactive (radioligand) therapy each year. That number is expected to rise further ...

In 2025, the therapeutic landscape for advanced prostate cancer in Germany is marked by remarkable progress—ranging from radioligand therapy to precision imaging and immunotherapy. This article ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Prostate Cancer Risk Increases By 45% Among Men ... "By enabling access to this targeted radioligand therapy prior to chemotherapy, we are not only broadening treatment options, but also ...